[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619145":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":23,"interventions":29,"overallOfficials":17,"centralContacts":17,"locations":17,"responsibleParty":35,"collaborators":17,"id":37,"slug":17,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":17,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":17,"enrollmentInfo":44,"targetDuration":17,"studyType":47,"phases":17,"briefSummary":48,"conditions":49,"keywords":17,"overallStatus":51,"whyStopped":17,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":17},{"fullName":5,"class":6},"March Biosciences Inc","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Assess long term safety of MB-105 in patients who received MB-105","SAEs","15 Years",[14],{"measure":15,"description":16,"timeFrame":12},"Assess long term efficacy of MB-105 in patients who received MB-105","Time to progression\u002Frelapse in those who have not yet relapsed and overall survival",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.","Patients who previously received MB-105 and consent to participate",[24],{"label":25,"type":17,"description":26,"interventionNames":27},"Open Observation","All patients who previously received MB-105 on another study",[28],"Biological: MB-105",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":17},"BIOLOGICAL","MB-105","This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study",[25],{"type":36,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100619145",false,"NCT07340814","A Long-term Follow-up Study of Patients Who Received MB-105","Inclusion Criteria:\n\nReceived MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements\n\nExclusion Criteria:\n\nN\u002FA","ALL","18 Years",{"count":45,"type":46},40,"ESTIMATED","OBSERVATIONAL","This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study",[50],"Any Patient Treated With MB-105","NOT_YET_RECRUITING","2026-01-06",{"date":54,"type":55},"2026-01-14","ACTUAL",{"date":57,"type":46},"2026-02-27",{"date":59,"type":46},"2040-10-15",{"name":5,"class":6}]